tetano
Editor, Senior Moderator
Drugs Context
. 2020 May 26;9:2020-5-2.
doi: 10.7573/dic.2020-5-2. eCollection 2020.
A Brief Note on Randomized Controlled Trials and Compassionate/Off-Label Use of Drugs in the Early Phases of the COVID-19 Pandemic
Matteo Bassetti[SUP] 1 2 [/SUP], Paolo Pelosi[SUP] 3 4 [/SUP], Chiara Robba[SUP] 4 [/SUP], Antonio Vena[SUP] 1 2 [/SUP], Daniele Roberto Giacobbe[SUP] 1 2 [/SUP]
Affiliations
Abstract
Randomized controlled trials (RCTs) are the best way to find effective and acceptable safe treatments for COVID-19 and any possible future outbreak. However, caution is needed when comparing the number of participants in RCTs with that of patients with COVID-19 treated with compassionate and/or off-label drugs to support the hypothesis that the latter are preferred by clinicians as an alternative to the former.
Keywords: COVID-19; RCT; SARS-CoV-2; compassionate; coronavirus; off-label.
. 2020 May 26;9:2020-5-2.
doi: 10.7573/dic.2020-5-2. eCollection 2020.
A Brief Note on Randomized Controlled Trials and Compassionate/Off-Label Use of Drugs in the Early Phases of the COVID-19 Pandemic
Matteo Bassetti[SUP] 1 2 [/SUP], Paolo Pelosi[SUP] 3 4 [/SUP], Chiara Robba[SUP] 4 [/SUP], Antonio Vena[SUP] 1 2 [/SUP], Daniele Roberto Giacobbe[SUP] 1 2 [/SUP]
Affiliations
- PMID: 32523611
- PMCID: PMC7255468
- DOI: 10.7573/dic.2020-5-2
Abstract
Randomized controlled trials (RCTs) are the best way to find effective and acceptable safe treatments for COVID-19 and any possible future outbreak. However, caution is needed when comparing the number of participants in RCTs with that of patients with COVID-19 treated with compassionate and/or off-label drugs to support the hypothesis that the latter are preferred by clinicians as an alternative to the former.
Keywords: COVID-19; RCT; SARS-CoV-2; compassionate; coronavirus; off-label.